Library

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • 1995-1999  (2)
  • Schlüsselwörter Mammakarzinom • Knochenmetastasen • Strahlentherapie • Bisphosphonate •  (1)
  • breast cancer  (1)
  • PCR-Technik
Material
Years
Year
  • 1
    Electronic Resource
    Electronic Resource
    Springer
    Der Gynäkologe 32 (1999), S. 675-682 
    ISSN: 1433-0393
    Keywords: Key words Breast cancer • Bone metastases • ; Radiotherapy • Bisphosphonates • Palliation • Surgery • Chemotherapy ; Schlüsselwörter Mammakarzinom • Knochenmetastasen • Strahlentherapie • Bisphosphonate • ; Palliation • Chirurgie • Chemotherapie
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Zusammenfassung Knochenmetastasen beim Mammakarzinom verweisen nicht nur – wie andere Metastasen auch – auf die Inkurabilität des zugrunde liegenden Leidens, sondern gehen mit spezifischen Komplikationen einher. Insbesondere Knochenschmerzen und pathologische Frakturen beeinträchtigen die Lebensqualität der betroffenen Frauen. Die Vermeidung oder Verminderung skelettaler Komplikationen besitzt daher höchste Priorität im Behandlungskonzept. Zwei Therapieoptionen bieten sich an: lokale und systemische. Zu den ersten zählen die Strahlenbehandlung und chirurgisch-orthopädische Maßnahmen. Die vier Säulen der systemischen Behandlung sind die Hormon- und Chemotherapie, die antiresorptive Therapie mit Bisphosphonaten und die Behandlung mit zentral- und/oder peripher wirksamen Analgetika. Voraussetzung für den Therapieerfolg ist die enge Kooperation von Gynäkologen, internistischen Onkologen, Radiotherapeuten, Chirurgen/Orthopäden, Schmerztherapeuten, und Endokrinologen (im Falle eines Hyperkalzämiesyndroms). Bei ausschließlich ossärer Metastasierung können die Überlebenszeiten der Patientinnen viele Jahre betragen. Um so wichtiger ist die frühzeitige Einleitung der adäquaten Therapiemaßnahme. Einen besonderen Stellenwert besitzen die Bisphosphonate, da ihre Hauptwirkung in der Vermeidung skelettaler Komplikationen besteht. Diese Substanzklasse ersetzt keine antineoplastische Therapie sondern ergänzt alle weiteren Behandlungskonzepte. Eine einmal eingeleitete Bisphosphonattherapie sollte auch bei ossärer Progression lebenslang weitergeführt werden.
    Notes: Summary Like other metastases, bone metastases in breast cancer patients are not only a sign of the incurable nature of the underlying disease, but are also associated with specific complications. In particular, bone pain and pathological fractures impair the quality of life of those affected. Any treatment concept must therefore place the highest priority on preventing or reducing skeletal complications. There are two treatment options – local and systemic. Local therapy includes radiotherapy as well as surgical and orthopedic measures. The four pillars of systemic treatment are hormone therapy and chemotherapy, antiresorptive therapy with bisphosphonates and treatment with centrally and/or peripherally acting analgesics. A precondition for successful treatment is close cooperation between gynecologists, internists/oncologists, radiotherapists, surgeons/orthopedists, pain specialists and endocrinologists (in the presence of a hypercalcemic syndrome). Patients with breast cancer associated solely with osseous metastasis may survive for a number of years. It is therefore all the more important to start appropriate therapeutic measures in good time. Bisphosphonates play a particularly valuable role, since their main effect lies in the prevention of skeletal complications. Rather than replacing antineoplastic therapy, this class of substances supplements other treatments. Once started, bisphosphonate therapy should be given life-long, even in the event of osseous progression.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    ISSN: 1573-7217
    Keywords: tumour cell detection ; cathepsin D ; breast cancer ; micrometastasis ; prognostic factor
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Patients with an elevated level of cathepsin D in breast cancer tissue have an adverse prognosis. This study evaluated the prognostic relevance of cathepsin D detection in disseminated tumour cells in bone marrow. Bone marrow was sampled intraoperatively from both anterior iliac crests in 290 patients with primary breast cancer. Interphase cells were enhanced and stained immunocytologically with two antibodies: BM2, which detects tumour-associated glycoprotein TAG 12, which is typically expressed by almost all breast cancer cells, and the anti-cathepsin D antibody. 67 of 149 BM2-positive women (45%) developed metastatic disease (median follow-up time: 69 months). Of these, 15 were cathepsin D-positive (22%). Patients with cathepsin D-positive cells in bone marrow (n = 26; 9%) had a significantly shorter metastasis-free interval (38 months) compared with women who were cathepsin D-negative (64.5 months). The worst prognosis was seen in patients positive for both markers (30.5 months), followed by those who were cathepsin D-negative and BM2-positive (48 months). The detection of cathepsin D on disseminated tumour cells characterises a subgroup of patients with a poorer prognosis who should undergo more aggressive adjuvant systemic therapy.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...